Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the effect of mild (Child-Pugh A, score
5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment on the pharmacokinetics,
safety and tolerability of nintedanib, in comparison with a control group with normal hepatic
function following oral administration of nintedanib as single dose.